ISPOR - PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.

Full Text

PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.

Abstract

Authors

J. Lachaine M.D. Jain J. Bibeau J.P. Marino G. Ball

Back to Volume 24, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now